GPT and Recurrent upper respiratory tract infections: The most frequently reported TEAEs (≥2% of patients in any treatment group) through week 12 were upper respiratory tract infection (UPA 15 mg: 9.5%, PBO: 6.5%) and increased alanine aminotransferase (UPA 15 mg: 5.3%, PBO: 1.2%).